Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Microbot Medical Inc.MBOT · Entity 6767 | Director | April 01, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Microbot Medical Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.37 · Expires 2036-04-01 | Direct | 10,000 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 10,000 · Balance 10,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 20:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001493152-26-015147 · ownership.xml · derivative · entry 1 Wenderow Tal Baruch · CIK 0001822324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.01 per share · 10,000 shares Expires 2036-04-01 Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001493152-25-004277 · ownership.xml · derivative · entry 1 Wenderow Tal Baruch · CIK 0001822324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.01 per share · 10,000 shares Expires 2035-01-28 Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 21:15 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 74,218 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-23-039529 · ownership.xml · derivative · entry 1 Wenderow Tal Baruch · CIK 0001822324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,218 Underlying: Common Stock, par value $0.01 per share · 74,218 shares Expires 2033-11-02 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 10:37 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 16,637 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001493152-22-026612 · ownership.xml · derivative · entry 1 Wenderow Tal Baruch · CIK 0001822324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,637 Underlying: Common Stock, par value $0.01 per share · 16,637 shares Expires 2032-09-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| September 29, 2021 Filed Oct 5, 2021 22:27 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 13,571 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024680 · ownership.xml · derivative · entry 1 Wenderow Tal Baruch · CIK 0001822324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,571 Underlying: Common Stock, par value $0.01 per share · 13,571 shares Expires 2031-09-29 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 29, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| August 14, 2020 Filed Sep 9, 2020 20:45 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 4,902 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001493152-20-017485 · ownership.xml · derivative · entry 1 Wenderow Tal Baruch · CIK 0001822324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,902 Underlying: Common Stock, par value $0.01 per share · 4,902 shares Expires 2030-08-14 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan (the "Plan"): (a) on February 14, 2021, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.